| |
Original Artikel |
Datum |
Titel |
Autoren Alle Autoren |
| 1 |
[GO] |
2026―Mrz―26 |
A Rabbit-Derived Single-Domain Antibody Fused to the Streptococcus zooepidemicus Zag Protein Engineered for SARS-CoV-2 Neutralization and Extended Half-Life |
Isa Moutinho, Rafaela Marimon, Rúben D. M. Silva, Célia Fernandes, Lurdes Gano, João D. G. Correia, et al. (+3) João Gonçalves, Luís Tavares, Frederico Aires-da-Silva |
| 2 |
[GO] |
2023―Jul―12 |
Exploring the Impact of Herbal Therapies on COVID-19 and Influenza: Investigating Novel Delivery Mechanisms for Emerging Interventions |
Lucas Fornari Laurindo, Ledyane Taynara Marton, Giulia Minniti, Victória Dogani Rodrigues, Rodrigo Buzinaro Suzuki, Virgínia Maria Cavallari Strozze Catharin, et al. (+2) Rakesh Kumar Joshi, Sandra Maria Barbalho |
| 3 |
[GO] |
2023―Jun―09 |
A Review on the Impact of the SARS-CoV-2 Omicron Subvariant on Elderly Patients with Diverse Co-Morbidities |
Avinash Khadela, Shruti Soni, Kaivalya Megha, Shivam Bhagat, Vivek P. Chavda |
| 4 |
[GO] |
2023―Mai―12 |
Aptamers as Insights for Targeting SARS-CoV-2 |
Suna Karadeniz Saygılı, Anna Szymanowska, Gabriel Lopez-Berestein, Cristian Rodriguez-Aguayo, Paola Amero |
| 5 |
[GO] |
2022―Sep―01 |
Why Are We Still Talking about Ivermectin? Editorial Note on Stone et al. Changes in SpO2 on Room Air for 34 Severe COVID-19 Patients after Ivermectin-Based Combination Treatment |
Seth H. Pincus |
| 6 |
[GO] |
2022―Sep―01 |
Changes in SpO2 on Room Air for 34 Severe COVID-19 Patients after Ivermectin-Based Combination Treatment: 62% Normalization within 24 Hours |
Jaqueline C. Stone, Pisirai Ndarukwa, David E. Scheim, Barry M. Dancis, Jerome Dancis, Martin G. Gill, Colleen Aldous |
| 7 |
[GO] |
2022―Jul―22 |
Aged Population and Immunocompromised Patients: Impact on SARS-CoV-2 Variants and Treatment Outcomes |
Vivek P. Chavda, Mahesh T. Chhabria, Vasso Apostolopoulos |
| 8 |
[GO] |
2021―Dez―01 |
In Silico Evaluation of Different Flavonoids from Medicinal Plants for Their Potency against SARS-CoV-2 |
H. R. Abd El-Mageed, Doaa A. Abdelrheem, Md. Oliullah Rafi, Md. Takim Sarker, Khattab Al-Khafaji, Md. Jamal Hossain, et al. (+2) Raffaele Capasso, Talha Bin Emran |
| 9 |
[GO] |
2021―Okt―26 |
A Comprehensive Overview of the Newly Emerged COVID-19 Pandemic: Features, Origin, Genomics, Epidemiology, Treatment, and Prevention |
Md. Takim Sarker, A. Q. Fuad Hasan, Md. Oliullah Rafi, Md. Jamal Hossain, H. R. Abd El-Mageed, Reem M. Elsapagh, et al. (+2) Raffaele Capasso, Talha Bin Emran |
| 10 |
[GO] |
2021―Okt―26 |
Nucleic Acid Vaccines for COVID-19: A Paradigm Shift in the Vaccine Development Arena |
Vivek P. Chavda, Md Kamal Hossain, Jayesh Beladiya, Vasso Apostolopoulos |
| 11 |
[GO] |
2021―Okt―15 |
Peptides in COVID-19 Clinical Trials-A Snapshot |
Kai Hilpert |
| 12 |
[GO] |
2021―Okt―12 |
Is the Gut Microbiome a Target for Adjuvant Treatment of COVID-19? |
Kai Hilpert |
| 13 |
[GO] |
2021―Sep―16 |
Clinical Efficacy and Safety of Antiviral Drugs in the Extended Use against COVID-19: What We Know So Far |
Md. Jamal Hossain, Tabassum Jannat, Shejuti Rahman Brishty, Urmi Roy, Saikat Mitra, Md. Oliullah Rafi, et al. (+4) Md. Rabiul Islam, Mst. Luthfun Nesa, Md. Ariful Islam, Talha Bin Emran |
| 14 |
[GO] |
2021―Aug―04 |
A COVID-19 Overview and Potential Applications of Cell Therapy |
Diana Aparecida Dias Câmara, Allan Saj Porcacchia, Nelson Foresto Lizier, Paulo Luiz De-Sá-Júnior |
| 15 |
[GO] |
2021―Jul―16 |
Computational Chemistry to Repurposing Drugs for the Control of COVID-19 |
Majid Hassanzadeganroudsari, Amir Hossein Ahmadi, Niloufar Rashidi, Md Kamal Hossain, Amanda Habib, Vasso Apostolopoulos |
| 16 |
[GO] |
2021―Mai―13 |
Overview of COVID-19 Disease: Virology, Epidemiology, Prevention Diagnosis, Treatment, and Vaccines |
Iman Salahshoori, Noushin Mobaraki-Asl, Ahmad Seyfaee, Nasrin Mirzaei Nasirabad, Zahra Dehghan, Mehrdad Faraji, et al. (+4) Mina Ganjkhani, Aziz Babapoor, Seyede Zahra Shadmehr, Ali Hamrang |
|
